Avalo Therapeutics CMO Doyle Mittie's Stock Option Exercise and Sale

On June 23, 2026, Doyle Mittie, Chief Medical Officer of Avalo Therapeutics, exercised stock options for 1,450 shares at $8.04 per share and immediately sold the same number of shares at $18.00 per share, resulting in a net profit of approximately $14,448. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Following these transactions, Mittie now holds 51,776 shares of common stock and 116,871 stock options. The exercised stock options were part of a grant that vests 25% on January 28, 2026, with the remainder vesting monthly over three years, subject to continued service.